Verstovsek, Srdan <br/><br/>
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.  [electronic resource] 

 -  Blood  Aug 2012 
 - 1202-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-02-414631  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Case-Control Studies<br/>Clinical Trials, Phase I as Topic--statistics & numerical data<br/>Clinical Trials, Phase II as Topic--statistics & numerical data<br/>Clinical Trials, Phase III as Topic--statistics & numerical data<br/>Cohort Studies<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Janus Kinase 1--antagonists & inhibitors<br/>Janus Kinase 2--antagonists & inhibitors<br/>Male<br/>Middle Aged<br/>Nitriles<br/>Primary Myelofibrosis--diagnosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyrimidines<br/>Randomized Controlled Trials as Topic--statistics & numerical data<br/>Survival Analysis<br/>Survivors--statistics & numerical data<br/>Treatment Outcome<br/>Assessment of Medication Adherence